Arvinas to present ARV-102 Parkinson’s data at MDS congress

Arvinas (ARVN) will present Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 targets LRRK2, a protein linked to Parkinson’s and PSP. The presentations will include biomarker and oculomotor data. Arvinas is a clinical-stage biotech company focused on protein degradation therapies.

Arvinas Inc. (ARVN) began a Phase 1/2 trial for ARV-6723, a PROTAC targeting HPK1 in advanced solid tumors. The global study will assess safety, pharmacokinetics, and antitumor activity as a monotherapy and with pembrolizumab. Preclinical data showed potent HPK1 degradation and antitumor effects. ARVN stock closed at $7.59, up 0.13% in pre-market trading.

Arvinas (ARVN) reported Q2 2026 revenue of $249.7M, up from $22.4M a year earlier, driven by FDA approval of VEPPANU and a licensing deal with Rigel. The FDA approved VEPPANU, the first PROTAC therapy, for advanced breast cancer. Arvinas licensed global rights to Rigel, generating $50M in milestone revenue and $62.5M in license revenue. The company expects three Phase 1 readouts in the next year. Cash reserves fell to $567.9M from $685.4M due to operational expenses.

Arvinas (ARVN) reported Q2 2026 revenue of $249.7 million, including $62.5 million from a Rigel license and a $50 million Pfizer (PFE) milestone tied to FDA approval of VEPPANU. Net income was $169.4 million and diluted EPS $2.58. Cash and marketable securities were $567.9 million, funding into 2H 2028. The call also discussed clinical timing updates and an FDA-requested delay for ARV-102.

Arvinas shares rose 13.2% after the company reported Q2 2026 results before the open. EPS was $2.58 versus a forecast loss of $0.38, and revenue was $249.7 million versus $58.61 million expected, including licensing and milestone items tied to VEPPANU and Rigel. Management cited VEPPANU approval, upcoming Phase 1 data, and a cash runway into H2 2028.

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –